guest ::
| Home > Articles > Published articles > Challenges associated with biomarker-based classification systems for Alzheimer's disease |
| Home > Articles > Published articles > Challenges associated with biomarker-based classification systems for Alzheimer's disease |
(Institut d'Investigació Biomèdica Sant Pau) (Institut d'Investigació Biomèdica Sant Pau) (Institut d'Investigació Biomèdica Sant Pau) (Institut d'Investigació Biomèdica Sant Pau) (Institut d'Investigació Biomèdica Sant Pau) (Institut d'Investigació Biomèdica Sant Pau) (Institut d'Investigacions Biomèdiques August Pi i Sunyer) (Institut d'Investigació Biomèdica Sant Pau) (Institut d'Investigació Biomèdica Sant Pau) (Institut d'Investigació Biomèdica Sant Pau)| Date: | 2018 |
| Abstract: | We aimed to evaluate the consistency of the A/T/N classification system. We included healthy controls, mild cognitive impairment, and dementia patients from Alzheimer's disease Neuroimaging Initiative. We assessed subject classification consistency with different biomarker combinations and the agreement and correlation between biomarkers. Subject classification discordance ranged from 12. 2% to 44. 5% in the whole sample; 17. 3%-46. 4% in healthy controls; 11. 9%-46. 5% in mild cognitive impairment, and 1%-35. 7% in dementia patients. Amyloid, but not neurodegeneration biomarkers, showed good agreement both in the whole sample and in the clinical subgroups. Amyloid biomarkers were correlated in the whole sample, but not along the Alzheimer's disease continuum (as defined by a positive amyloid positron emission tomography). Neurodegeneration biomarkers were poorly correlated both in the whole sample and along the Alzheimer's disease continuum. The relationship between biomarkers was stage-dependent. Our findings suggest that the current A/T/N classification system does not achieve the required consistency to be used in the clinical setting. |
| Grants: | Instituto de Salud Carlos III PI14-01126 Instituto de Salud Carlos III PI17-01019 Instituto de Salud Carlos III PI13-01532 Instituto de Salud Carlos III PI16-01825 Instituto de Salud Carlos III PI14-1561 Instituto de Salud Carlos III IF15-00060 Agència de Gestió d'Ajuts Universitaris i de Recerca 2014SGR-0235 |
| Note: | Altres ajuts: This work was also supported by research grants from the Carlos III Institute of Health, Spain and the CIBERNED program (Program 1, Alzheimer Disease to Alberto Lleó and SIGNAL study, www.signalstudy.es), partly funded by Fondo Europeo de Desarrollo Regional (FEDER), Unión Europea, "Una manera de hacer Europa". This work has also been supported by a "Marató TV3" grant (20141210 to Juan Fortea and 044412 to Rafael Blesa) and by Generalitat de Catalunya and a grant from the Fundació Bancaria La Caixa to Rafael Blesa. I. Illán-Gala is supported by the i-PFIS grant from the FIS, Instituto de Salud Carlos III and the Rio Hortega grant (CM17/00074) from "Acción estratégica en Salud 2013-2016" and the European Social Fund. USPHS NIH grants awarded to M.J.d.L. include: AG13616, AG022374, AG12101, and AG057570. |
| Rights: | Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, i la comunicació pública de l'obra, sempre que no sigui amb finalitats comercials, i sempre que es reconegui l'autoria de l'obra original. No es permet la creació d'obres derivades.  |
| Language: | Anglès |
| Document: | Article ; recerca ; Versió publicada |
| Subject: | Alzheimer's disease ; Biomarkers ; Magnetic resonance ; Positron emission tomography ; Classification systems ; Diagnosis |
| Published in: | Alzheimer's & Dementia : Diagnosis, Assessment & Disease Monitoring, Vol. 10 (april 2018) , p. 346-357, ISSN 2352-8729 |
